Evommune Gross Profit

The latest gross profit for EVMN is $9M as of June 2026. That compares with $1.9M in the prior-year period — up 368.7% year over year. That is below the Healthcare sector average of $66B. Investors often review this figure alongside Evommune's historical trend and sector peers before judging valuation or financial health.

Over the past year, EVMN's gross profit moved from $1.9M to $9M — a 368.7% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Evommune's operating scale or balance-sheet position.

Against Healthcare companies, EVMN currently prints $9M for gross profit, while the sector average sits near $66B. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Evommune's growth, margins, and balance sheet.

A gross profit figure of $9M for EVMN is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $66B. Explore the charts below for those layers of context.

After noting EVMN's gross profit ($9M), review year-over-year change from $1.9M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.